The Global Initiative for Chronic Obstructive Lung Disease (GOLD) has released its 2026 report (Version 1.3, dated December 8 ...

Regular walking reduces symptom flare-ups for people with chronic obstructive pulmonary disease, even if they live in an area ...

AstraZeneca’s tozorakimab reduced disease flare ups in patients with COPD, suggesting IL-33-targeted antibodies could offer broad potential in pulmonary diseases.

The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion.

Over 52 weeks, adults with moderate to very severe eosinophilic COPD receiving tezepelumab vs. placebo had less healthcare ...

Breathing exercises remain an underused, safe, low-cost therapy for COPD — and new research shows a humor-infused technique ...

COPD is one of the top 10 leading cause of death in the U.S., the CDC says.

Connect Biopharma (NASDAQ:CNTB) reported top-line results from its Seabreeze STAT Phase II study of rademikibart in patients ...

Rademikibart significantly reduced treatment failure and new moderate-to-severe COPD exacerbations in the Seabreeze STAT ...

If you have COPD, the sounds made by your lungs can help your doctor evaluate the state of your airways and whether your treatment is working. Types of COPD lung sounds include wheezing, crackling, ...

Patients with COPD who experience at least 1 moderate exacerbation may be at increased risk of all-cause mortality.

Breathlessness and cough are common symptoms of several lung conditions, including interstitial lung disease (ILD), asthma, and chronic obstructive pulmonary disease (COPD). Because their symptoms can ...